The U.S. FDA issued a complete response letter in October 2023 for Dupixent (dupilumab) in treating chronic hives but has now approved the monoclonal antibody for the indication. The approval makes ...

The researchers identified the structure of this machine, the mitochondrial pyruvate carrier (MPC), and 50 years since its discovery, have shown how it operates like the lock on a canal to transport ...

The FDA had rejected the companies’ initial application in 2023, requesting additional data after the pharma firms reported ...

This claim is based on the use of pulse radar devices by experts to create high-resolution images deep underground beneath the structures, in the same way that sonar radar is used to map the depths of ...

The urgent need for an advanced centre on bridge research, a special window for clearance of iconic structures, and preservation of all records of building such bridges — these are some of the ...

In addition to COPD, Dupixent is approved in Japan in certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), prurigo nodularis and chronic spontaneous ...

As per the analyst, the transformation consists of inventory and debt reduction, and divestitures, together with an agile organizational structure ... Eastman Chemical Company (NYSE:EMN) operates ...

The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD ...

The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD) in ...

A new study led by researchers at the Earth-Life Science Institute (ELSI) at Institute of Science Tokyo has uncovered a surprising role for calcium in shaping life's earliest molecular structures.

Dupixent, representing about 30% of total sales, but we expect new products will mitigate the eventual generic competition (likely after 2030). Sanofi’s operating structure allows for cost ...